Showing 2751-2760 of 5956 results for "".
- Study: Essilor’s Stellest Lens Slows Down Myopia Progression in Children by More Than 60% After One Yearhttps://modernod.com/news/study-essilors-stellest-lens-slows-down-myopia-progression-in-children-by-more-than-60-after-one-year/2478339/Essilor reported that after 1 year of an ongoing clinical trial, there was a more than 60% slowdown in myopia progression in children on average with the recently launched Stellest lens, compared to a single vision lenses. Essilor launched the Stellest lens in the Wenzhou Medical Universit
- Fauci Offers Defense of Why Americans Can Trust the Approval Process for a Potential COVID-19 Vaccinehttps://modernod.com/news/fauci-offers-defense-of-why-americans-can-trust-the-approval-process-for-a-potential-covid-19-vaccine/2478314/A potential COVID-19 vaccine is likely to approved in November or December, but the announcement of any such vaccine will not be based in any way on a political timeline, infectious disease expert Anthony Fauci, MD, said Tuesday evening during The Atlantic Festival, according to a FierceHealthcar
- Gyroscope Therapeutics Granted FDA Fast Track Designation for Investigational Gene Therapy for Dry AMDhttps://modernod.com/news/gyroscope-therapeutics-granted-fda-fast-track-designation-for-investigational-gene-therapy-for-dry-amd/2478305/Gyroscope Therapeutics announced that the FDA has granted Fast Track designation to GT005 for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). GT005 is an investigational one-time AAV-based gene therapy that is delivered under the retina and is i
- CooperVision Recaps Complimentary Contact Lens Program for Essential Hospital Workershttps://modernod.com/news/coopervision-recaps-complimentary-contact-lens-program-for-essential-hospital-workers/2478307/Over the past 4 months, CooperVision’s Essential Hospital Workers Complimentary Contact Lens Program enabled eye care professionals to provide support to patients working on the front lines of the COVID-19 pandemic. By the program’s conclusion on August 31, nearly 570 optometry practices from 46
- Keeler Partners With Medical Device Maker Olleyeshttps://modernod.com/news/keeler-partners-with-medical-device-maker-olleyes/2478278/Keeler has announced a partnership with Olleyes, a developer of eye care-based office and home-based diagnostic products. Terms of the deal were not disclosed. Olleyes is the maker of VisuALL VRP (Virtual Reality Perimetry), a platform designed for standardized and mobile assessment
- First Patient Dosed in Phase 3 Clinical Trial of Dextenza for the Treatment of Post-Surgical Ocular Inflammation and Pain in Childrenhttps://modernod.com/news/ocular-therapeutix-announces-first-patient-dosed-in-phase-3-clinical-trial-of-dextenza-for-the-treatment-of-post-surgical-ocular-inflammation-and-pain-in-children/2478274/Ocular Therapeutix announced that it has dosed the first patients in a phase 3 clinical trial of Dextenza (dexamethasone ophthalmic insert) 0.4 mg for the treatment of post-surgical ocular inflammation and pain in children following cataract surgery. “We are pleased to announce the start o
- Staar Surgical Announces Completion of Patient Enrollment in EVO Implantable Lens US Clinical Trialhttps://modernod.com/news/staar-surgical-announces-completion-of-patient-enrollment-in-evo-implantable-lens-us-clinical-trial/2478275/Staar Surgical has announced that patient enrollment for the primary study analysis cohort of 300 subjects has been achieved in its FDA clinical trial, “A Multicenter Clinical Evaluation of the EVO/EVO+ Visian Implantable Collamer Lens.” Primary study analysis will be conducted when 300 primary e
- Researchers Are Able to Visualize the Retina’s Function at the Cellular Levelhttps://modernod.com/news/researchers-are-able-to-visualize-the-retinas-function-at-the-cellular-level/2478271/While there is no cure for blindness and macular degeneration, scientists have accelerated the process to find a cure by visualizing the inner workings of th
- Kala Pharmaceuticals to Host Key Opinion Leader Symposium on Unmet Need in Dry Eye Disease and Potential for Eysuvishttps://modernod.com/news/kala-pharmaceuticals-to-host-key-opinion-leader-symposium-on-unmet-need-in-dry-eye-disease-and-potential-for-eysuvis/2478270/Kala Pharmaceuticals announced that it will host a key opinion leader symposium on the unmet need in dry eye disease and the potential for Eysuvis as a short-term treatment for the signs and symptoms of the disease. The event will be held virtually on Thursday, September 17, 2020, beginning at 8
- Visible Genomics Launches DNA Age-Related Macular Degeneration Testinghttps://modernod.com/news/visible-genomics-launches-dna-age-related-macular-degeneration-testing/2478264/Visible Genomics, a Chicago-area genetics testing company, has announced the launch of a new noninvasive genetic eye test that the company says determines a patient’s likelihood of contracting age-related macular degeneration (AMD). While it’s estimated that up to 70% of AMD cases are due